Adrulipase alfa clinical trials
Also written MS1819.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses adrulipase alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- MS1819
- 5
Studies by the year they started
5 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses adrulipase alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study to Assess an Enteric Microgranule Formulation of Adrulipase in Patients With Cystic FibrosisCompletedPhase 2Entero TherapeuticsNCT05719311Written as adrulipase
- OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic FibrosisCompletedPhase 2Entero TherapeuticsNCT04375878Written as MS1819
- OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic FibrosisCompletedPhase 2Entero TherapeuticsNCT03746483Written as MS1819
- Phase 2 Combination Study With Escalating Doses of MS1819-SD on Top of a Stable Dose of PPEsCompletedPhase 2AzurRx SASNCT04302662Written as MS1819-SD
- A Phase IIa Study With Escalating Dose of MS1819-SDCompletedPhase 2AzurRx SASNCT03481803Written as MS1819-SD
Codes
What other systems call adrulipase alfa · ClinicalTrials.gg INT018209
- UNII (FDA) V6AP1D8NNWADRULIPASE ALFAOne source FDA
- NCI Thesaurus C184896Adrulipase AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | V6AP1D8NNW | ADRULIPASE ALFA | One source FDA |
| NCI Thesaurus | C184896 | Adrulipase Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.